1
|
Hellström S, Sajanti A, Srinath A, Bennett C, Girard R, Cao Y, Frantzén J, Koskimäki F, Falter J, Lyne SB, Rantamäki T, Takala R, Posti JP, Roine S, Puolitaival J, Jänkälä M, Kolehmainen S, Rahi M, Rinne J, Castrén E, Koskimäki J. Brain Plasticity Modulator p75 Neurotrophin Receptor in Human Urine after Different Acute Brain Injuries-A Prospective Cohort Study. Biomedicines 2024; 12:112. [PMID: 38255217 PMCID: PMC10813252 DOI: 10.3390/biomedicines12010112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 12/27/2023] [Accepted: 01/03/2024] [Indexed: 01/24/2024] Open
Abstract
Acute brain injuries (ABIs) pose a substantial global burden, demanding effective prognostic indicators for outcomes. This study explores the potential of urinary p75 neurotrophin receptor (p75NTR) concentration as a prognostic biomarker, particularly in relation to unfavorable outcomes. The study involved 46 ABI patients, comprising sub-cohorts of aneurysmal subarachnoid hemorrhage, ischemic stroke, and traumatic brain injury. Furthermore, we had four healthy controls. Samples were systematically collected from patients treated at the University Hospital of Turku between 2017 and 2019, at early (1.50 ± 0.70 days) and late (9.17 ± 3.40 days) post-admission time points. Urinary p75NTR levels, measured by ELISA and normalized to creatinine, were compared against patients' outcomes using the modified Rankin Scale (mRS). Early urine samples showed no significant p75NTR concentration difference between favorable and unfavorable mRS groups. In contrast, late samples exhibited a statistically significant increase in p75NTR concentrations in the unfavorable group (p = 0.033), demonstrating good prognostic accuracy (AUC = 70.9%, 95% CI = 53-89%, p = 0.03). Assessment of p75NTR concentration changes over time revealed no significant variation in the favorable group (p = 0.992) but a significant increase in the unfavorable group (p = 0.009). Moreover, p75NTR concentration was significantly higher in ABI patients (mean ± SD 40.49 ± 28.83-65.85 ± 35.04 ng/mg) compared to healthy controls (mean ± SD 0.54 ± 0.44 ng/mg), irrespective of sampling time or outcome (p < 0.0001). In conclusion, late urinary p75NTR concentrations emerged as a potential prognostic biomarker for ABIs, showing increased levels associated with unfavorable outcomes regardless of the specific type of brain injury. While early samples exhibited no significant differences, the observed late increases emphasize the time-dependent nature of this potential biomarker. Further validation in larger patient cohorts is crucial, highlighting the need for additional research to establish p75NTR as a reliable prognostic biomarker across various ABIs. Additionally, its potential role as a diagnostic biomarker warrants exploration.
Collapse
Affiliation(s)
- Santtu Hellström
- Department of Neurosurgery, Division of Clinical Neurosciences, Turku University Hospital, University of Turku, P.O. Box 52, Hämeentie 11, 20521 Turku, Finland
- Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland
| | - Antti Sajanti
- Department of Neurosurgery, Division of Clinical Neurosciences, Turku University Hospital, University of Turku, P.O. Box 52, Hämeentie 11, 20521 Turku, Finland
| | - Abhinav Srinath
- Neurovascular Surgery Program, Section of Neurosurgery, The University of Chicago Medicine and Biological Sciences, 5841 S. Maryland, Chicago, IL 60637, USA (C.B.)
| | - Carolyn Bennett
- Neurovascular Surgery Program, Section of Neurosurgery, The University of Chicago Medicine and Biological Sciences, 5841 S. Maryland, Chicago, IL 60637, USA (C.B.)
| | - Romuald Girard
- Neurovascular Surgery Program, Section of Neurosurgery, The University of Chicago Medicine and Biological Sciences, 5841 S. Maryland, Chicago, IL 60637, USA (C.B.)
| | - Ying Cao
- Department of Radiation Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA
| | - Janek Frantzén
- Department of Neurosurgery, Division of Clinical Neurosciences, Turku University Hospital, University of Turku, P.O. Box 52, Hämeentie 11, 20521 Turku, Finland
| | - Fredrika Koskimäki
- Neurocenter, Acute Stroke Unit, Turku University Hospital, P.O. Box 52, 20521 Turku, Finland
| | - Johannes Falter
- Department of Neurosurgery, University Medical Center of Regensburg, 93053 Regensburg, Germany
| | - Seán B. Lyne
- Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Tomi Rantamäki
- Laboratory of Neurotherapeutics, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences and Drug Research Program, 00100 Helsinki, Finland
- Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, 00100 Helsinki, Finland
| | - Riikka Takala
- Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, University of Turku, P.O. Box 52, 20521 Turku, Finland
| | - Jussi P. Posti
- Department of Neurosurgery, Division of Clinical Neurosciences, Turku University Hospital, University of Turku, P.O. Box 52, Hämeentie 11, 20521 Turku, Finland
| | - Susanna Roine
- Neurocenter, Acute Stroke Unit, Turku University Hospital, P.O. Box 52, 20521 Turku, Finland
| | - Jukka Puolitaival
- Department of Neurosurgery, Oulu University Hospital, P.O. Box 25, 90029 Oulu, Finland
| | - Miro Jänkälä
- Department of Neurosurgery, Oulu University Hospital, P.O. Box 25, 90029 Oulu, Finland
| | - Sulo Kolehmainen
- Neuroscience Center, HiLIFE, University of Helsinki, P.O. Box 63, 00014 Helsinki, Finland
| | - Melissa Rahi
- Department of Neurosurgery, Division of Clinical Neurosciences, Turku University Hospital, University of Turku, P.O. Box 52, Hämeentie 11, 20521 Turku, Finland
| | - Jaakko Rinne
- Department of Neurosurgery, Division of Clinical Neurosciences, Turku University Hospital, University of Turku, P.O. Box 52, Hämeentie 11, 20521 Turku, Finland
| | - Eero Castrén
- Neuroscience Center, HiLIFE, University of Helsinki, P.O. Box 63, 00014 Helsinki, Finland
| | - Janne Koskimäki
- Department of Neurosurgery, Division of Clinical Neurosciences, Turku University Hospital, University of Turku, P.O. Box 52, Hämeentie 11, 20521 Turku, Finland
- Department of Neurosurgery, Oulu University Hospital, P.O. Box 25, 90029 Oulu, Finland
- Neuroscience Center, HiLIFE, University of Helsinki, P.O. Box 63, 00014 Helsinki, Finland
| |
Collapse
|
2
|
Sajanti A, Hellström S, Girard R, Frantzen J, Umemori J, Koskimäki F, Lyne SB, Falter J, Rantamäki T, Nazir K, Gharat B, Posti J, Roine S, Takala R, Kolehmainen S, Cao Y, Li Y, Heino I, Rahi M, Rinne J, Nieminen AI, Castren E, Koskimaki J. Abstract TP234: Different Type Of Acute Brain Injuries Share Similar Pattern Of Lipidomic Profile Changes In Human Serum. Stroke 2023. [DOI: 10.1161/str.54.suppl_1.tp234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Background:
Neuronal recovering processes after acute brain injuries such as aneurysmal subarachnoid hemorrhage (aSAH), ischemic stroke (IS) and traumatic brain injury (TBI) are complex including brain plasticity and synaptic regeneration mechanisms. Temporal changes in lipidomic profile after different acute brain injuries may reveal new insights about brain plasticity, recovery and biomarker development after acute injury.
Hypotheses:
Measurable temporal changes in serum lipidomic profile may be similar irrespective of the type of the brain injury and may reveal conserved molecular aberrations after different types of acute brain injuries. These common changes may also be associated to outcome and serve as possible biomarkers.
Methods:
Prospective cohort (n=74) consisted of IS (n=30), aSAH (n=31) and TBI (n=13) patients. Serum samples were collected in two time points after the insult (early 24-48h and late 120-192h). Lipidomic profiling of 1153 lipids was performed using Lipidyzer Platform. The lipidomics data was analyzed with Metaboanalyst for ANOVA, PCA, heatmap, box plots with following settings: missing values were imputated with KNN using 20% cutoff, log-transformed and auto-scaled.
Results:
We identified four diacylglycerols (DAG), one cholesterol ester (CE), seven triacylglycerols (TAG) and one sphingomyelin (SM) which showed increased levels in late serum samples across all types of brain injuries (p<0.05, FDR corrected). Four free fatty acids (FFA) and two phosphatidylethanolamines (PE) levels were decreased in late serum samples across all injury types (p<0.05, FDR corrected).
Conclusion:
Changes in lipidomic profiles across time were identified. This suggests common lipidomic characteristics irrespective of the type of brain insult and encourage further studies. Interestingly, lipidomic profiles may be associated to recovery after acute brain injury and further analyses of this data will follow.
Collapse
Affiliation(s)
- Antti Sajanti
- Div of Clinical Neurosciences, Dept of Neurosurgery, Turku Univ Hosp and Univ of Turku, Piikkio, Finland
| | - Santtu Hellström
- Div of Clinical Neurosciences, Dept of Neurosurgery, Turku Univ Hosp and Univ of Turku, Seinäjoki, Finland
| | | | | | | | - Fredrika Koskimäki
- Div of Clinical Neurosciences, Dept of Neurosurgery, Turku Univ Hosp and Univ of Turku, Turku, Finland
| | - Sean B. Lyne
- Dept of Neurosurgery, Brigham and Women’s Hosp, Harvard Med Sch, Boston, Massachusetts, Boston, MA
| | - Johannes Falter
- Dept of Neurosurgery, Univ Med Cntr of Regensburg, Regensburg, Germany, Regensburg, Germany
| | | | - Kenneth Nazir
- Metabolomics Unit, Institute for Molecular Medicine Finland, Univ of Helsinki, 000014, Finland, Turku, Finland
| | - Bajera Gharat
- Metabolomics Unit, Institute for Molecular Medicine Finland, Univ of Helsinki, 000014, Finland, Helsinki, Finland
| | | | | | | | | | - Ying Cao
- Dept of radiation oncology, Kansas City, KS
| | - Yan Li
- Cntr for Rsch Informatics, The Univ of Chicago, Chicago, IL, Chicago, IL
| | - Iiro Heino
- Div of Clinical Neurosciences, Dept of Neurosurgery, Turku Univ Hosp and Univ of Turku, Turku, Finland
| | | | | | - Anni I Nieminen
- Metabolomics Unit, Institute for Molecular Medicine Finland, Univ of Helsinki, 000014, Finland, Helsinki, Finland
| | - Eero Castren
- Neuroscience Cntr, HiLIFE, Univ of Helsinki, Helsinki, Finland
| | | |
Collapse
|
3
|
Sajanti A, Lyne SB, Girard R, Frantzén J, Rantamäki T, Heino I, Cao Y, Diniz C, Umemori J, Li Y, Takala R, Posti JP, Roine S, Koskimäki F, Rahi M, Rinne J, Castrén E, Koskimäki J. A comprehensive p75 neurotrophin receptor gene network and pathway analyses identifying new target genes. Sci Rep 2020; 10:14984. [PMID: 32917932 PMCID: PMC7486379 DOI: 10.1038/s41598-020-72061-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Accepted: 08/24/2020] [Indexed: 12/13/2022] Open
Abstract
P75 neurotrophic receptor (p75NTR) is an important receptor for the role of neurotrophins in modulating brain plasticity and apoptosis. The current understanding of the role of p75NTR in cellular adaptation following pathological insults remains blurred, which makes p75NTR’s related signaling networks an interesting and challenging initial point of investigation. We identified p75NTR and related genes through extensive data mining of a PubMed literature search including published works related to p75NTR from the past 20 years. Bioinformatic network and pathway analyses of identified genes (n = 235) were performed using ReactomeFIViz in Cytoscape based on the highly reliable Reactome functional interaction network algorithm. This approach merges interactions extracted from human curated pathways with predicted interactions from machine learning. Genome-wide pathway analysis showed total of 16 enriched hierarchical clusters. A total of 278 enriched single pathways were also identified (p < 0.05, false discovery rate corrected). Gene network analyses showed multiple known and new targets in the p75NTR gene network. This study provides a comprehensive analysis and investigation into the current knowledge of p75NTR signaling networks and pathways. These results also identify several genes and their respective protein products as involved in the p75NTR network, which have not previously been clearly studied in this pathway. These results can be used to generate novel hypotheses to gain a greater understanding of p75NTR in acute brain injuries, neurodegenerative diseases and general response to cellular damage.
Collapse
Affiliation(s)
- Antti Sajanti
- Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Hämeentie 11, P.O. Box 52, 20521, Turku, Finland
| | - Seán B Lyne
- Neurovascular Surgery Program, Section of Neurosurgery, The University of Chicago Medicine and Biological Sciences, 5841 S. Maryland, Chicago, IL, 60637, USA
| | - Romuald Girard
- Neurovascular Surgery Program, Section of Neurosurgery, The University of Chicago Medicine and Biological Sciences, 5841 S. Maryland, Chicago, IL, 60637, USA
| | - Janek Frantzén
- Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Hämeentie 11, P.O. Box 52, 20521, Turku, Finland
| | - Tomi Rantamäki
- Laboratory of Neurotherapeutics, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences and Drug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
| | - Iiro Heino
- Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Hämeentie 11, P.O. Box 52, 20521, Turku, Finland
| | - Ying Cao
- Neurovascular Surgery Program, Section of Neurosurgery, The University of Chicago Medicine and Biological Sciences, 5841 S. Maryland, Chicago, IL, 60637, USA
| | - Cassiano Diniz
- Neuroscience Center, HiLIFE, University of Helsinki, Box 63, 00014, Helsinki, Finland
| | - Juzoh Umemori
- Neuroscience Center, HiLIFE, University of Helsinki, Box 63, 00014, Helsinki, Finland
| | - Yan Li
- Neurovascular Surgery Program, Section of Neurosurgery, The University of Chicago Medicine and Biological Sciences, 5841 S. Maryland, Chicago, IL, 60637, USA.,Center for Research Informatics, The University of Chicago, Chicago, IL, USA
| | - Riikka Takala
- Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, POB 52, 20521, Turku, Finland.,Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland
| | - Jussi P Posti
- Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Hämeentie 11, P.O. Box 52, 20521, Turku, Finland
| | - Susanna Roine
- Division of Clinical Neurosciences, Department of Cerebrovascular Diseases, Turku University Hospital and University of Turku, Hämeentie 11, P.O. Box 52, 20521, Turku, Finland
| | - Fredrika Koskimäki
- Division of Clinical Neurosciences, Department of Cerebrovascular Diseases, Turku University Hospital and University of Turku, Hämeentie 11, P.O. Box 52, 20521, Turku, Finland
| | - Melissa Rahi
- Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Hämeentie 11, P.O. Box 52, 20521, Turku, Finland
| | - Jaakko Rinne
- Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Hämeentie 11, P.O. Box 52, 20521, Turku, Finland
| | - Eero Castrén
- Neuroscience Center, HiLIFE, University of Helsinki, Box 63, 00014, Helsinki, Finland
| | - Janne Koskimäki
- Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Hämeentie 11, P.O. Box 52, 20521, Turku, Finland. .,Department of Psychiatry, Central Hospital of Southern Ostrobothnia, Hanneksenrinne 7, 60220, Seinäjoki, Finland.
| |
Collapse
|
4
|
Koskimäki F, Bernard J, Yong J, Arndt N, Carroll T, Lee SK, Reder AT, Javed A. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One 2018; 13:e0209326. [PMID: 30576361 PMCID: PMC6303064 DOI: 10.1371/journal.pone.0209326] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 12/04/2018] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume loss needs further examination in the context of specific MS treatment. OBJECTIVES To examine whole and segmented gray, white, thalamic, and corpus callosum volume loss in stable patients receiving natalizumab for 2-5 years. METHODS This was a retrospective study of 20 patients undergoing treatment with natalizumab for 24-68 months. Whole brain volume loss was determined with SIENA. Gray and white matter segmentation was done using FAST. Thalamic and corpus callosum volumes were determined using Freesurfer. T1 relaxation values of chronic hypointense lesions (black holes) were determined using a quantitative, in-house developed method to assess lesion evolution. RESULTS Over a mean of 36.6 months, median percent brain volume change (PBVC) was -2.0% (IQR 0.99-2.99). There was decline in gray (p = 0.001) but not white matter (p = 0.6), and thalamic (p = 0.01) but not corpus callosum volume (p = 0.09). Gray matter loss correlated with PBVC (Spearman's r = 0.64, p = 0.003) but not white matter (Spearman's r = 0.42, p = 0.07). Age significantly influenced whole brain volume loss (p = 0.010, multivariate regression), but disease duration and baseline T2 lesion volume did not. There was no change in T1 relaxation values of lesions or T2 lesion volume over time. All patients remained clinically stable. CONCLUSIONS These results demonstrate that brain volume loss in MS is primarily driven by gray matter changes and may be independent of clinically effective treatment.
Collapse
Affiliation(s)
- Fredrika Koskimäki
- Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Turku, Finland
| | - Jacqueline Bernard
- Department of Neurology, Oregon Health Science University, Portland, Oregon, United States of America
| | - Jeong Yong
- Northwestern University, Biomedical Engineering, Chicago, Illinois, United States of America
| | - Nancy Arndt
- Department of Neurology, The University of Chicago, Chicago, Illinois, United States of America
| | - Timothy Carroll
- Department of Radiology, The University of Chicago, Chicago, Illinois, United States of America
| | - Seon-Kyu Lee
- Department of Radiology, The University of Chicago, Chicago, Illinois, United States of America
| | - Anthony T. Reder
- Department of Neurology, The University of Chicago, Chicago, Illinois, United States of America
| | - Adil Javed
- Department of Neurology, The University of Chicago, Chicago, Illinois, United States of America
| |
Collapse
|